Trading was heavy with 8,040K shares changing hands in the last trading session. Trading volume was up 377.57% over the stocks average daily volume.
Traders are feeling more bearish on the company lately as inferred by the change in short interest. The firm experienced a rise in short interest from September 29, 2017 to October 13, 2017 of 3.99%. Short shares grew 350,448 over that period. With short interest at 9,134,573 and short average daily volume at 1,019,264, the short-interest ratio is 9.0 and the percentage of shorted shares was 0.07% on October 13.
These firms have modified their investment in ACHN. Numeric Investors LLC downsized its ownership by selling 538,252 shares a decrease of 18.3% from 06/30/2017 to 09/30/2017. Numeric Investors LLC controls 2,397,092 shares worth $10,763,000. The value of the position overall is down by 20.1%. Renaissance Technologies LLC augmented its investment by buying 312,675 shares an increase of 48.8% in the quarter. Renaissance Technologies LLC now controls 953,975 shares valued at $4,283,000. The total value of its holdings increased 45.5%.
As of quarter end Schwab Charles Investment Management Inc had acquired 68,271 shares growing its position 14.9%. The value of the investment in (ACHN) went from $2,100,000 to $2,360,000 a change of 12.4% since the last quarter. Millennium Management LLC trimmed its position by shedding 2,609,991 shares a decrease of 86.5% as of 09/30/2017. Millennium Management LLC currently owns 406,200 shares with a value of $1,824,000. The value of the position overall is down by 86.8%.
September 17 investment analysts at Chardan Capital reiterated a “Neutral” rating on the stock. Ladenburg Thalmann Financial Services lowered the price target on September 12 changing the forecast from $9.00 to $6.50 and issued a “Buy” recommendation.
September 12 investment analysts at Robert W. Baird left the company rating at “Neutral” projecting a price of $4.00.
Equity analyst Maxim Group released research on ACHN and giving a rating of “Buy” and setting a price target of $7.00. Equity analyst Chardan Capital lowered the price target on August 9 changing the price objective from $5.00 to $4.00 with a rating of “Neutral”.
In the market the company is trading up from yesterday’s close of 3.03. The P/E ratio is N/A and the market cap is 463.20M. In the last earnings report the EPS was $-0.49 with 137.86M shares outstanding.
Achillion Pharmaceuticals, Inc., launched on August 5, 1998, is a biopharmaceutical company. The Company is involved in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system. The complement system is part of the human innate immune system. Its clinical compound from its complement inhibitor platform is ACH-4471. ACH-4471 is a potent and specific inhibitor of factor D, which demonstrated complete inhibition of the complement alternative pathway in human healthy volunteers in a Phase I clinical trial..